Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Retained Earnings: 2009-2024

Historic Retained Earnings for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to -$1.7 billion.

  • Ironwood Pharmaceuticals' Retained Earnings rose 1.68% to -$1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 billion, marking a year-over-year increase of 1.68%. This contributed to the annual value of -$1.7 billion for FY2024, which is 0.05% up from last year.
  • As of FY2024, Ironwood Pharmaceuticals' Retained Earnings stood at -$1.7 billion, which was up 0.05% from -$1.7 billion recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Retained Earnings registered a high of -$696.4 million during FY2022, and its lowest value of -$1.7 billion during FY2023.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Retained Earnings value was -$1.7 billion (recorded in 2024), while the average stood at -$1.4 billion.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Retained Earnings soared by 36.05% in 2021 and then slumped by 143.92% in 2023.
  • Ironwood Pharmaceuticals' Retained Earnings (Yearly) stood at -$1.5 billion in 2020, then surged by 36.05% to -$937.6 million in 2021, then increased by 25.73% to -$696.4 million in 2022, then tumbled by 143.92% to -$1.7 billion in 2023, then rose by 0.05% to -$1.7 billion in 2024.